U.S., Feb. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07420959) titled 'ABBV-383 for the Treatment of Relapsed Refractory Waldenstrom Macroglobulinemia' on Feb. 05.
Brief Summary: This phase I/II trial studies the side effects and best dose of ABBV-383 and to see how well it works in treating patients with Waldenstrom macroglobulinemia that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). ABBV-383 is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (a...